{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:22:27Z","timestamp":1790666547060,"version":"4.1.0"},"reference-count":35,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Sacituzumab govitecan has been recently approved by the USFDA and EMA for the treatment of patients with metastatic triple-negative breast cancer (mTNBC). We report real-world safety and effectiveness in patients with mTNBC receiving sacituzumab govitecan treatment at a breast cancer centre in Germany.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Data from patients who had received sacituzumab govitecan as treatment for mTNBC, in both de novo and relapsed disease, at the Kliniken Essen-Mitte, Essen, Germany, were collected through institutional records. Data were analysed for safety parameters and survival outcomes and reported using descriptive statistics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Patients ( N\u2009=\u200943) received a median (range) of 5 (1\u201328) cycles of sacituzumab govitecan and were followed up for a median of 12.9\u2009months. The most reported adverse events (AEs) of any grade were alopecia ( n\u2009=\u200939; 90.7%), diarrhoea ( n\u2009=\u200916; 37.2%), fatigue ( n\u2009=\u200915, 34.9%), anaemia ( n\u2009=\u200915, 34.9%) and neutropenia ( n\u2009=\u200914, 32.6%). AEs\u2009\u2a7e\u2009Grade 3 with the highest incidence were neutropenia ( n\u2009=\u200912; 27.9%) and diarrhoea ( n\u2009=\u20098; 18.6%). In eight (18.6%) patients, dose of sacituzumab govitecan dose was reduced due to patients\u2019 clinical condition prior to commencing treatment; in further 17 (39.5%) patients, sacituzumab govitecan dose had to be reduced or treatment interrupted on account of AEs associated with the drug after treatment had commenced. Median progression-free survival and median overall survival were calculated to be 5.0and 13.1\u2009months, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The real-world safety and effectiveness profile of sacituzumab govitecan in patients with mTNBC are in line with clinical trial data. Further studies are required to guide optimal use of sacituzumab govitecan against mTNBC, especially in context of management of accompanying AEs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359231200454","type":"journal-article","created":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T01:05:11Z","timestamp":1695949511000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":38,"title":["Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany"],"prefix":"10.1177","volume":"15","author":[{"given":"Mattea","family":"Reinisch","sequence":"first","affiliation":[{"name":"Interdisciplinary Breast Unit, Kliniken Essen-Mitte, Henricistrasse 92, Essen 45136, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Bruzas","sequence":"additional","affiliation":[{"name":"Interdisciplinary Breast Unit, Kliniken Essen-Mitte, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Spoenlein","sequence":"additional","affiliation":[{"name":"Interdisciplinary Breast Unit, Kliniken Essen-Mitte, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyendra","family":"Shenoy","sequence":"additional","affiliation":[{"name":"Interdisciplinary Breast Unit, Kliniken Essen-Mitte, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Traut","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakima","family":"Harrach","sequence":"additional","affiliation":[{"name":"Interdisciplinary Breast Unit, Kliniken Essen-Mitte, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ouafaa","family":"Chiari","sequence":"additional","affiliation":[{"name":"Interdisciplinary Breast Unit, Kliniken Essen-Mitte, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efsthatia","family":"Cremer","sequence":"additional","affiliation":[{"name":"Interdisciplinary Breast Unit, Kliniken Essen-Mitte, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beyhan","family":"Ataseven","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Essen, Germany"},{"name":"Department of Obstetrics and Gynecology, University Hospital, Ludwig-Maximilians-Universit\u00e4t, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Gubelt","sequence":"additional","affiliation":[{"name":"Zentralapotheke, Kliniken Essen-Mitte, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherko","family":"Kuemmel","sequence":"additional","affiliation":[{"name":"Interdisciplinary Breast Unit, Kliniken Essen-Mitte, Essen, Germany"},{"name":"Department of Gynecology with Breast Center, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,9,28]]},"reference":[{"key":"bibr1-17588359231200454","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-3045"},{"key":"bibr2-17588359231200454","doi-asserted-by":"publisher","DOI":"10.3816\/CBC.2009.n.005"},{"key":"bibr3-17588359231200454","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-016-4080-9"},{"key":"bibr4-17588359231200454","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines\u00ae breast cancer, version 4, https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf (2022, accessed 01 August 2022)."},{"key":"bibr5-17588359231200454","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.010"},{"key":"bibr6-17588359231200454","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03399"},{"key":"bibr7-17588359231200454","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32531-9"},{"key":"bibr8-17588359231200454","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202809"},{"key":"bibr9-17588359231200454","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615"},{"key":"bibr10-17588359231200454","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706450"},{"key":"bibr11-17588359231200454","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105215"},{"key":"bibr12-17588359231200454","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.009"},{"key":"bibr13-17588359231200454","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802905"},{"key":"bibr14-17588359231200454","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920915980"},{"key":"bibr15-17588359231200454","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.8297"},{"key":"bibr16-17588359231200454","doi-asserted-by":"publisher","DOI":"10.1021\/cr900097c"},{"key":"bibr17-17588359231200454","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814213"},{"key":"bibr18-17588359231200454","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.03.005"},{"key":"bibr19-17588359231200454","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028485"},{"key":"bibr20-17588359231200454","unstructured":"United States Food and Drug Administration. FDA grants regular approval to sacituzumab govitecan for triple-negative breast cancer, https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-regular-approval-sacituzumab-govitecan-triple-negative-breast-cancer (2021, accessed 8 July 2022)."},{"key":"bibr21-17588359231200454","unstructured":"European Medicines Agency. Trodelvy, https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/trodelvy#authorisation-details-section (2021, accessed 8 July 2022)."},{"key":"bibr22-17588359231200454","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.06.002"},{"key":"bibr23-17588359231200454","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-022-06602-7"},{"key":"bibr24-17588359231200454","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00439-5"},{"key":"bibr25-17588359231200454","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.10.003"},{"key":"bibr26-17588359231200454","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.1071"},{"key":"bibr27-17588359231200454","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.004"},{"key":"bibr28-17588359231200454","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01002"},{"key":"bibr29-17588359231200454","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS602"},{"key":"bibr30-17588359231200454","doi-asserted-by":"publisher","DOI":"10.1055\/a-1519-7089"},{"key":"bibr31-17588359231200454","unstructured":"European Medicines Agency. Trodelvy, summary of product characteristics, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/trodelvy-epar-product-information_en.pdf (2022, accessed 1 January 2023)."},{"key":"bibr32-17588359231200454","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.03.074"},{"key":"bibr33-17588359231200454","unstructured":"ClinicalTrials.gov. NCT05520723: Multicenter, open-label, single arm, phase II clinical trial to improve sacituzumab govitecan\u2019s tolerance inpatients with metastatic triple-negative breast cancer, https:\/\/clinicaltrials.gov\/study\/NCT05520723 (accessed 13 July 2023)."},{"key":"bibr34-17588359231200454","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00467-1"},{"key":"bibr35-17588359231200454","unstructured":"U.S. Food & Drug Administration. FDA approves sacituzumab govitecan-hziy for HR-positive breast cancer, https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-sacituzumab-govitecan-hziy-hr-positive-breast-cancer (2023, accessed 13 July 2023)."}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359231200454","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359231200454","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359231200454","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:29:06Z","timestamp":1777588146000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359231200454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":35,"alternative-id":["10.1177\/17588359231200454"],"URL":"https:\/\/doi.org\/10.1177\/17588359231200454","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"article-number":"17588359231200454"}}